FDA Draft Guidance on Genome Editing Could Accelerate CRISPR Therapeutics Rare Disease Pipeline
The FDA has issued draft guidance that may speed approval pathways for rare disease therapies using genome editing technologies, potentially benefiting CRISPR Therapeutics' pipeline of six clinical-stage candidates.